MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

[News]

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

More... (https://www.news-medical.net/news/20240725/MD-Anderson-and-Summit-Therapeutics-partner-to-accelerate-ivonescimab-development.aspx)